NCT03282643View on ClinicalTrials.gov

Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

February 16, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

April 1, 2019

Conditions
Neoplasms
Interventions
DRUG

Rivaroxaban 10 MG

Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture

DRUG

Rivaroxaban 20 MG

Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture

DRUG

Low-molecular-weight heparin

0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)

Trial Locations (1)

100038

Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital, Beijing

All Listed Sponsors
lead

Capital Medical University

OTHER

NCT03282643 - Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients | Biotech Hunter | Biotech Hunter